Boston Trust Walden Corp Has $71.50 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Boston Trust Walden Corp increased its stake in shares of Haemonetics Co. (NYSE:HAE) by 13.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 915,722 shares of the medical instruments supplier’s stock after purchasing an additional 106,114 shares during the period. Boston Trust Walden Corp owned approximately 1.82% of Haemonetics worth $71,500,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Creative Planning bought a new stake in shares of Haemonetics in the 2nd quarter valued at about $368,000. Quarry LP acquired a new stake in Haemonetics in the second quarter worth $39,000. Handelsbanken Fonder AB boosted its position in shares of Haemonetics by 23.9% during the third quarter. Handelsbanken Fonder AB now owns 17,095 shares of the medical instruments supplier’s stock worth $1,374,000 after purchasing an additional 3,300 shares in the last quarter. Dynamic Advisor Solutions LLC increased its position in shares of Haemonetics by 10.1% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 20,154 shares of the medical instruments supplier’s stock valued at $1,620,000 after buying an additional 1,848 shares in the last quarter. Finally, West Coast Financial LLC raised its stake in Haemonetics by 2.2% during the 3rd quarter. West Coast Financial LLC now owns 47,182 shares of the medical instruments supplier’s stock worth $3,792,000 after buying an additional 1,013 shares during the period. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on HAE. Barrington Research reiterated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research report on Wednesday, December 4th. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a report on Friday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. began coverage on Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Trading Down 0.8 %

Shares of Haemonetics stock opened at $68.90 on Monday. Haemonetics Co. has a 12-month low of $67.26 and a 12-month high of $97.97. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The business’s 50 day moving average is $78.61 and its 200-day moving average is $79.07. The stock has a market cap of $3.46 billion, a P/E ratio of 28.59, a P/E/G ratio of 1.07 and a beta of 0.39.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. During the same quarter last year, the firm posted $0.99 EPS. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Equities research analysts predict that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.